Encochleated atovaquone - Matinas BioPharma

Drug Profile

Encochleated atovaquone - Matinas BioPharma

Latest Information Update: 15 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma; National Institute of Allergy and Infectious Diseases
  • Class Antiprotozoals; Naphthoquinones
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pneumocystis pneumonia

Most Recent Events

  • 10 Oct 2015 Pharmacodynamics data from a preclinical trial in pneumocystis pneumonia released by Matinas BioPharma
  • 10 Oct 2015 Pharmacokinetics data from a preclinical trial in pneumocystis pneumonia released by Matinas BioPharma
  • 30 Jan 2015 Preclinical trials in Pneumocystis pneumonia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top